Hyderabad-based vaccine manufacturer Indian Immunologicals Limited (IIL) is all ready to launch vaccines for Hepatitis A (Hep A) and for Measles and Rubella (MR) in 2023.

At the Genomics India Conference 2023 in Bengaluru recently, Dr K Anand Kumar, Managing Director, Indian Immunologicals Limited said that there are multiple human vaccine projects underway currently at IIL. "We are working on live attenuated COVID-19 and dengue vaccines, bi-valent typhoid vaccine and vaccines for polio, chikungunya and zika", he said.

Besides human vaccines, the company is also working on multiple animal vaccines projects such as Foot Rot (Sheep), Canine 10-in-1 (Dog), MegaVac- KeC (Dog), Lumpy Skin Disease (Cattle), Mastitis (Cattle) 4 in 1, gE deleted IBR marker vaccine (Cattle).

With a revenue generation of Rs 815 crore during FY21-22, the company is now looking towards clocking in a figure of Rs 1000 crore this fiscal. IIL has also recently forayed into a novel space of developing fish vaccines using genomic technologies.

"There are many areas of vaccine development where genomics can be used such as to understand pathogenesis, to identify virulence factors, to identify conserved regions, reduce the number of valency, instant sequencing of new threats and comparison with known organisms to help figure out a strategy to develop vaccines", Dr Anand added.